Cormay co. is an accredited producer of high quality diagnostic reagents and distributor of the best medical laboratory equipment. Nowadays, it appears to be the biggest Polish producer and exporter of diagnostic reagents, possessing 5 % of investments in the Polish market of clinical chemistry and hematology. The company exports its products to over 30 countries in the world, such as Germany, Austria, France, Greece, Turkey, England, China, Portugal, Czech Republic, Slovakia, Latvia, Ukraine or India. It proves great potential of the enterprise, which has been recently appreciated.

On February 8th 2012 Cormay co. was granted in the plebiscite “The Best Co-partnership in the Stock Market”, which is organized every year by the economic journal “Puls Biznesu” (The Business Pulse). The company was awarded after detailed research of almost 200 analysts, brokers and investment advisers.

Financial market agents agreed on that the first prize in the category “Success of the 2011” belongs to the Cormay co. Nonetheless, future remains the most important for the investors of the broker’s board. Cormay appeared to be the leader in these terms as well. As the most potent company it was granted the first prize in the “Development perspectives of 2012” category. Considerably high notes in the remaining classes emplaced Cormay co. in third place of the general ranking.

The company’s mission is obtaining full satisfaction of the client utilizing the offered products, advices and experience, which is followed by continuous and rapid development. It would not be possible to this extend if it was not for its president, Tomasz Tuora. Since he bought the shares of Cormay co. in 2006 and took the office of the board’s chairman, he has done a great work to realize its business vision. Over years Cormay co. overtook some foreign companies that could not handle their financial problems: Orphee – Swiss producer of hematology equipment, and Irish Innovation Enterprise. It increased the company’s value and allowed succesful expansion of the European market, which led to current capitalization of Cormay co. accounted for nearly 108 million EUR.

What about the future?

The president of Cormay co. is preparing to take over another diagnostic company, American NASDAQ, specialized in cancer research. It is very important step as the United States comprise the greatest market of medical diagnostics in the world (39 % of total shares), which was not yet explored by Cormay. There are also some expansion plans towards Western Europe and Soth America.

Yet expansion is not the most important. Tomasz Tuora recognises innovativeness as a vital concern to the progress of companies dealing with medical diagnostics. This is why he relies on the best science and business experts. Currently, they are working on the new technology breakthrough – a hi-tech blood analyser, which is planned to be introduced to the market in 2013. There is no doubt that Cormay co. deserves its awarded titles.

Source: pzcormay.pl, twarzebiznesu.pl

Red.: Anna Drzazga